In-Vitro Diagnostics (IVD) Market Report: Market Expected to Increase to $76 Billion by 2023, Increasing its Influence over Healthcare Spending Globally

Dublin, May 05, 2017 -- Research and Markets has announced the addition of the "Global In-Vitro Diagnostics (IVD) Market: Analysis and Forecast 2017-2023 (Focus on Product Type, Test Type, Application, and Competitive Landscape)" report to their offering.

IVD is expected to increase to $76 billion by 2023 and increase its influence over healthcare spending globally.

The category's rate of growth is accelerating due to a number of key macro forces, such as demand from emerging economies, aging population, evolving clinician attitudes, and a much needed push towards theranostics and personalized medicine. The molecular diagnostics (MDx) segment has continually outperformed the broader IVD category, and is a key driver of this market's growth.

The In-Vitro Diagnostic (IVD) sector is playing a central role in the shifting the healthcare and drug discovery landscape. Invigorated by the demand for changes in the healthcare environment and driven by a wave of molecular advances, the in-vitro diagnostic sector is actively engaged in innovation of new tools and technologies. Present day healthcare systems are already strained under the burden of a rising demand and soaring costs; and this trend is projected to exacerbate in coming years. The current challenges tend to be chronic age-related conditions such as cardiovascular diseases, cancer, and neurological diseases, and these will grow more prevalent as population demographics shift upwards.

The report includes the company profiles for leading players in the IVD market which enables the readers understand the current competitive scenario that prevails in this industry. Some of the key player include Thermo Fisher, Roche, Abbott, Siemens Healthineers, Becton, Dickinson, Johnson & Johnson, Qiagen, and Danaher Corporation.

Key Topics Covered:

Executive Summary

1 Research Scope and Methodology
1.1 Scope of the Report
1.2 Global IVD Market Research Methodology

2 Market Overview

3 Market Dynamics

4 IVD Market Demand and Supply Analysis

5 Competitive Insights

6 Global IVD Market by Product Type, 2016-2023

7 Global IVD Market by Test Type, 2016-2023

8 Global IVD Market by Application Type, 2016-2023

9 Global IVD Market by End User Type, 2016-2023

10 Global IVD Market by Geography, 2016-2023

11 End User Perception About IVD

12 Market Analytics & Recommendations

13 Competitive Landscape

14 Company Profile

• Abbott Laboratories
• Agilent Technologies
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• F. Hoffmann-La Roche AG
• Financial
• GE Healthcare
• GlaxoSmithKline PLC (GSK)
• Illumina, Inc.
• Johnson & Johnson
• Laboratory Corporation of America Holdings
• Myriad Genetics, Inc.
• Novartis International AG
• Ortho Clinical Diagnostics
• Qiagen, Inc.
• Quest Diagnostics Incorporated
• Siemens Healthineers
• Thermo Fisher Scientific

For more information about this report visit http://www.researchandmarkets.com/research/l9488n/global_invitro

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: In Vitro Diagnostics